Acute Endocrine and Metabolic Emergencies Related to Neuroendocrine Tumors

Kaltsas, Gregory; Alexandraki, Krystallenia; Grossman, Ashley

doi:10.1002/9781119374800.ch29

Cited by 1 publication

(1 citation statement)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Surgical resection is the treatment of choice for local, locoregional disease and oligometastatic hepatic disease and as a means for cytoreduction in severe and uncontrolled CS [ 12 , 13 ]. However, somatostatin analogues (SSAs) remain the standard medical care for the hormonal symptoms in CS, even in a presurgical setting, in order to avoid a carcinoid crisis [ 14 , 15 ]. Somatostatin (SST-14), originally discovered in 1973, was considered at the time as a hypothalamic neuropeptide inhibiting the secretion of growth hormone but subsequently was shown to also inhibit gastrointestinal cell motility, secretion, and growth [ 16 ].…”

Section: Introductionmentioning

confidence: 99%

The Role of Somatostatin Analogues in the Control of Diarrhea and Flushing as Markers of Carcinoid Syndrome: A Systematic Review and Meta-Analysis

Alexandraki

Angelousi

Chatzellis

et al. 2023

JPM

View full text Add to dashboard Cite

Background: Somatostatin analogues (SSAs) are the cornerstone of treatment for carcinoid syndrome (CS)-related symptoms. The aim of this systematic review and meta-analysis is to evaluate the percentage of patients achieving partial (PR) or complete response (CR) with the use of long-acting SSAs in patients with CS. Methods: A systematic electronic literature search was conducted in PubMed, Cochrane, and Scopus to identify eligible studies. Any clinical trials reporting data on the efficacy of SSAs to alleviate symptoms in adult patients were considered as potentially eligible. Results: A total of 17 studies reported extractable outcomes (PR/CR) for quantitative synthesis. The pooled percentage of patients with PR/CR for diarrhea was estimated to be 0.67 (95% confidence interval (CI): 0.52–0.79, I2 = 83%). Subgroup analyses of specific drugs provided no evidence of a differential response. With regards to flushing, the pooled percentage of patients with PR/CR was estimated to be 0.68 (95% CI: 0.52–0.81, I2 = 86%). Similarly, no evidence of a significant differential response in flushing control was documented. Conclusions: We estimate there is a 67–68% overall reduction in symptoms of CS associated with SSA treatment. However, significant heterogeneity was detected, possibly revealing differences in the disease course, in management and in outcome definition.

show abstract